Astra, Daiichi Withdraw EU Application for Lung Cancer Drug

AstraZeneca Plc and Daiichi Sankyo Co. have voluntarily withdrawn an application for a lung cancer treatment in the European Union in a blow for the experimental drug.

The two companies said Tuesday they had pulled the authorization request for Dato-DXd for some patients with non-squamous non-small cell lung cancer following feedback from the EU’s drug advisory committee.